Pfizer ($PFE) will invest about $15.7 million (AU$21 million) to expand a plant in Adelaide, Australia, to increase the capacity of the active ingredient for Neulasta. No new jobs, however, are associated with the expansion, ABC in Australia reports. Site director Tony Mulcahy told the news service that the Adelaide facility makes the intermediate for pegfilgrastim, which is sent to a Pfizer plant in Croatia that does the fill-finish work. Story